Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-Targeted CAR-T Therapy in Relapsed and Refractory CEA+ Cancer
NCT04348643Phase 2Withdrawn
- Sponsor
- Chongqing Precision Biotech
- Start
- Feb 2020
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CEA CAR-T cells in solid tumor, lung cancer, colorectal cancer (CRC), liver cancer, pancreatic cancer (PC), sponsored by Chongqing Precision Biotech. Planned start Feb 2020; status: withdrawn.
02
Drugs
CEA CAR-T cells
03
Conditions
solid tumorlung cancercolorectal cancer (CRC)liver cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04348643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348643.